10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, 2008

Commission File Number: 001-32739

HealthSpring, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	20-1821898
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
9009 Carothers Parkway
Suite 501
Franklin, Tennessee	37067
(Address of Principal Executive Offices)	(Zip Code)

(615) 291-7000
(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ                                     No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer þ	Accelerated filer o	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o                                     No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

	Outstanding at April 29, 2008
Common Stock, Par Value $0.01 Per Share	58,891,359 Shares

TABLE OF CONTENTS

	Page
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)
Condensed Consolidated Balance Sheets at March 31, 2008 and December 31, 2007		1
Condensed Consolidated Statements of Income for the three months ended March 31, 2008 and 2007		2
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2008 and 2007		3
Notes to Condensed Consolidated Financial Statements		4
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		12
Item 3. Quantitative and Qualitative Disclosures about Market Risk		24
Item 4. Controls and Procedures		24
PART II — OTHER INFORMATION
Item 1. Legal Proceedings		25
Item 1A. Risk Factors		25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		26
Item 3. Defaults Upon Senior Securities		27
Item 4. Submission of Matters to a Vote of Security Holders		27
Item 5. Other Information		27
Item 6. Exhibits		28
Ex-10.1 Form of Restricted Share Award Agreement
Ex-31.1 Section 302 Certification of the CEO
Ex-31.2 Section 302 Certification of the CFO
Ex-32.1 Section 906 Certification of the CEO
Ex-32.2 Section 906 Certification of the CFO

Part I — FINANCIAL INFORMATION

Item 1: Financial Statements

HEALTHSPRING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

(unaudited)

	March 31,			December 31,
	2008			2007
Assets
Current assets:
Cash and cash equivalents	$	360,346		$	324,090
Accounts receivable, net		95,459			59,027
Investment securities available for sale		1,815			24,746
Investment securities held to maturity		15,771			16,594
Deferred income taxes		2,353			2,295
Prepaid expenses and other		4,619			4,913
Total current assets		480,363			431,665
Investment securities available for sale		38,413			39,905
Investment securities held to maturity		8,408			10,105
Property and equipment, net		23,776			24,116
Goodwill		588,001			588,001
Intangible assets, net		230,850			235,893
Restricted investments		10,454			10,095
Other		29,725			11,293
Total assets	$	1,409,990		$	1,351,073
Liabilities and Stockholders’ Equity
Current liabilities:
Medical claims liability	$	184,265		$	154,510
Accounts payable, accrued expenses and other current liabilities		38,202			27,489
Funds held for the benefit of members		103,767			82,231
Risk corridor payable to CMS		22,660			22,363
Current portion of long-term debt		22,500			18,750
Total current liabilities		371,394			305,343
Deferred income tax liability		88,933			90,552
Long-term debt, less current portion		270,000			277,500
Other long-term liabilities		5,286			6,323
Total liabilities		735,613			679,718
Stockholders’ equity:
Common stock, $0.01 par value, 180,000,000 shares authorized, 57,726,855 shares issued and 56,227,600 outstanding at March 31, 2008, 57,617,335 shares issued and 57,293,242 outstanding at December 31, 2007		577			576
Additional paid in capital		496,994			494,626
Retained earnings		197,276			176,218
Accumulated other comprehensive income		243			—
Treasury stock, at cost, 1,499,255 shares at March 31, 2008 and 324,093 shares at December 31, 2007		(20,713	)		(65	)
Total stockholders’ equity		674,377			671,355
Total liabilities and stockholders’ equity	$	1,409,990		$	1,351,073

See accompanying notes to condensed consolidated financial statements.

1

HEALTHSPRING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except share data)

(unaudited)

	Three Months Ended
	March 31,
	2008			2007
Revenue:
Premium:
Medicare	$	538,553		$	331,780
Commercial		2,337			13,240
Total premium revenue		540,890			345,020
Management and other fees		6,907			6,049
Investment income		4,811			5,248
Total revenue		552,608			356,317
Operating expenses:
Medicare		442,159			273,640
Commercial		2,023			10,055
Total medical expense		444,182			283,695
Selling, general and administrative		62,899			47,506
Depreciation and amortization		7,248			2,948
Interest expense		5,404			115
Total operating expenses		519,733			334,264
Income before equity in earnings of unconsolidated affiliate and income taxes		32,875			22,053
Equity in earnings of unconsolidated affiliate		101			21
Income before income taxes		32,976			22,074
Income tax expense		(11,918	)		(7,984	)
Net income	$	21,058		$	14,090
Net income per common share:
Basic	$	0.37		$	0.25
Diluted	$	0.37		$	0.25
Weighted average common shares outstanding:
Basic		56,861,343			57,233,712
Diluted		56,962,521			57,330,365

See accompanying notes to condensed consolidated financial statements.

2

HEALTHSPRING, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Three Months Ended
	March 31,
	2008			2007
Cash flows from operating activities:
Net income	$	21,058		$	14,090
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		7,248			2,948
Stock-based compensation		2,356			2,121
Amortization of deferred financing cost		598			54
Equity in earnings of unconsolidated affiliate		(101	)		(21	)
Deferred tax benefit		(1,808	)		(358	)
Increase (decrease) in cash due to:
Accounts receivable		(40,584	)		(14,176	)
Prepaid expenses and other current assets		294			(2,240	)
Medical claims liability		29,755			(9,635	)
Accounts payable, accrued expenses, and other current liabilities		10,713			(3,381	)
Deferred revenue		—			109,693
Other		(15,519	)		3,312
Net cash provided by operating activities		14,010			102,407
Cash flows from investing activities:
Purchase of property and equipment		(1,866	)		(4,282	)
Purchase of investment securities		(1,207	)		(16,747	)
Maturities of investment securities		28,526			2,237
Purchase of restricted investments		(359	)		(875	)
Net cash provided by (used in) investing activities		25,094			(19,667	)
Cash flows from financing activities:
Funds received for the benefit of the members		123,094			—
Funds withdrawn for the benefit of members		(101,558	)		—
Funds received for the benefit of the members, net		—			52,541
Payments on long-term debt		(3,750	)		—
Proceeds from stock options exercised		14			224
Purchase of treasury stock		(20,648	)		(5	)
Net cash (used in) provided by financing activities		(2,848	)		52,760
Net increase in cash and cash equivalents		36,256			135,500
Cash and cash equivalents at beginning of period		324,090			338,443
Cash and cash equivalents at end of period	$	360,346		$	473,943
Supplemental disclosures:
Cash paid for interest	$	5,339		$	62
Cash paid for taxes	$	4,660		$	2,039

See accompanying notes to condensed consolidated financial statements

3

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (1) Organization and Basis of Presentation

     HealthSpring, Inc, a Delaware corporation (the “Company”), was organized in October 2004 and began operations in March 2005 in connection with a recapitalization transaction accounted for as a purchase. The Company is a managed care organization that focuses primarily on Medicare, the federal government- sponsored health insurance program for United States citizens aged 65 and older, qualifying disabled persons, and persons suffering from end-stage renal disease. Through its health maintenance organization (“HMO”) subsidiaries, the Company operates Medicare Advantage health plans in the states of Alabama, Florida, Illinois, Mississippi, Tennessee and Texas and offers Medicare Part D prescription drug plans to persons in all 50 states. In addition, the Company uses its infrastructure and provider networks in Tennessee and Alabama to offer commercial health plans to employer groups. The Company also provides management services to healthcare plans and physician partnerships.

Basis of Presentation

     The accompanying condensed consolidated financial statements are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto of HealthSpring, Inc. as of and for the year ended December 31, 2007, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2008 (“2007 Form 10-K”).

     The accompanying unaudited condensed consolidated financial statements reflect the Company’s financial position as of March 31, 2008, the Company’s results of operations and cash flows for the three months ended March 31, 2008 and 2007.

     The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Act of 1934, as amended, the “Exchange Act.” Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations applicable to interim financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments (consisting of only normally recurring accruals) necessary to present fairly the Company’s financial position at March 31, 2008, and its results of operations and cash flows for the three months ended March 31, 2008 and 2007.

     The results of operations for the 2008 interim period are not necessarily indicative of the operating results that may be expected for the year ending December 31, 2008. Because of the Part D product benefit design, the company incurs prescription drug costs unevenly throughout the year, including a disproportionate amount of prescription drug costs in the first half of the year. In 2008, with the widening of the Part D risk corridors, the Company anticipates that the profitability of Part D will be more weighted toward the second half of the year than the Company has experienced in prior years.

     The preparation of the condensed consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. The most significant item subject to estimates and assumptions is the actuarial calculation for obligations related to medical claims. Other significant items subject to estimates and assumptions include the Company’s estimated risk adjustment payments receivable from the Centers for Medicare & Medicaid Services (“CMS”), the valuation of goodwill and intangible assets, the useful life of definite-lived assets, and certain amounts recorded related to the Part D program. Actual results could differ significantly from those estimates.

     The Company’s health plans are restricted from making distributions without appropriate regulatory notifications and approvals or to the extent such distributions would put them out of compliance with statutory net worth requirements or requirements under the Company’s credit facilities. At March 31, 2008, $396.8 million of the Company’s $435.2 million of cash, cash equivalents, investment securities and restricted investments were held by the Company’s HMO subsidiaries and subject to these dividend restrictions. The Company’s ability to make distributions is also limited by the Company’s credit facility.

4

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (2) Recently Adopted Accounting Pronouncements

     In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standard (“SFAS”) No. 157, “Fair Value Measurements” (“SFAS No. 157”). SFAS No. 157 establishes a common definition for fair value to be applied to U.S. GAAP requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. SFAS No. 157 is effective for financial assets and financial liabilities for fiscal years beginning after November 15, 2007. Issued in February 2008, FSP 157-1 “Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13” removed leasing transactions accounted for under Statement 13 and related guidance from the scope of SFAS No. 157. FSP 157-2 “Partial Deferral of the Effective Date of Statement 157” (“FSP 157-2”), deferred the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008.

     The implementation of SFAS No. 157 for financial assets and financial liabilities, effective January 1, 2008, did not have a material impact on the Company’s consolidated financial position and results of operations. The Company is currently assessing the impact of SFAS No. 157 for nonfinancial assets and nonfinancial liabilities on its consolidated financial position and results of operations.

     In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS No. 159”). SFAS No. 159, which amends SFAS No. 115, allows certain financial assets and liabilities to be recognized, at the Company’s election, at fair value, with any gains or losses for the period recorded in the statement of income. SFAS No. 159 included available-for-sale securities in the assets eligible for this treatment. Currently, the Company records the gains or losses for the period in the statement of comprehensive income and in the equity section of the balance sheet. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, and interim periods in those fiscal years. The Company adopted SFAS No. 159 effective January 1, 2008. The Company, at this time, has elected to not recognize any gains or losses for its available-for-sale securities in the statement of income, and has elected to not recognize any other financial assets or liabilities at fair value. Accordingly, there was no impact on the Company’s financial position or results of operations as a result of adopting the new standard.

     (3) Accounts Receivable

     Accounts receivable at March 31, 2008 and December 31, 2007 consisted of the following (in thousands):

	March 31,			December 31,
	2008			2007
Medicare premium receivables	$	73,430		$	37,777
Rebates		16,673			14,471
Commercial HMO premium receivables		243			1,049
Other		10,875			7,139
	$	101,221		$	60,436
Allowance for doubtful accounts		(1,612	)		(1,409	)
Total (including non-current receivables)	$	99,609		$	59,027

     Medicare premium receivables at March 31, 2008 include $69.4 million for receivables from CMS related to the accrual of retroactive risk adjustment payments (including $4.2 million classified as non-current and included in other assets on the Company’s balance sheet).

5

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     The Company’s Medicare premium revenue is subject to adjustment based on the health risk of its members. This process for adjusting premiums is referred to as the CMS risk payment methodology. Under the risk adjustment payment methodology, managed care plans must capture, collect, and report diagnosis code information to CMS. After reviewing the respective submissions, CMS establishes the payments to Medicare plans generally at the beginning of the calendar year, and then adjusts premium levels on two separate occasions on a retroactive basis. The first retroactive risk premium adjustment for a given fiscal year generally occurs during the third quarter of such fiscal year. This initial settlement (the “Initial CMS Settlement”) represents the updating of risk scores for the current year based on the prior year’s dates of service. CMS then issues a final retroactive risk premium adjustment settlement for that fiscal year in the following year (the “Final CMS Settlement”). Prior to 2007, the Company was unable to estimate the impact of either of these risk adjustment settlements, and as such recorded them upon notification from CMS of such amounts. In the first quarter of 2007, the Company began estimating and recording on a monthly basis the Initial CMS Settlement, as the Company concluded it had the ability to reasonably estimate such amounts. Similarly, in the fourth quarter of 2007, the Company estimated and recorded the Final CMS Settlement for 2007 (based on risk score data available at that time), as the Company concluded such amounts were estimable. During the 2008 first quarter the Company updated its estimated Final CMS Settlement payment amounts for 2007 based on its evaluation of additional diagnosis code information reported to CMS in 2008. This change in estimate related to the 2007 plan year resulted in an additional $12.0 million of premium revenue (and related accounts receivable from CMS) in the first quarter of 2008. The resulting impact on net income for the three months ended March 31, 2008, after the expense for risk sharing with providers and income tax expense, was $5.3 million. The Final CMS Settlement for 2006 was recorded during the second quarter of 2007 upon notification of such settlement amount from CMS.

     As of January 2008, the Company began estimating and recording on a monthly basis both the Initial CMS Settlement and the Final CMS Settlement for the 2008 CMS plan year. Results of operations for the 2007 first quarter do not include any premiums for estimated final CMS settlements. All such estimated amounts are periodically updated as necessary as additional diagnosis code information is reported to CMS and adjusted to actual amounts when the ultimate adjustment settlements are either received from CMS or the Company receives notification from CMS of such settlement amounts.

     Rebates for drug costs represent estimated rebates owed to the Company from prescription drug companies. The Company has entered into contracts with certain drug manufacturers which provide for rebates to the Company based on the utilization of specific prescription drugs by the Company’s members. Accounts receivable relating to unpaid health plan enrollee premiums are recorded during the period the Company is obligated to provide services to enrollees and do not bear interest. The Company does not have any off-balance sheet credit exposure related to its health plan enrollees. Other receivables primarily includes management fees receivable as well as amounts owed the Company from other health plans for the refund of certain medical expenses paid by the Company.

6

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (4) Fair Value Measurements

     Effective January 1, 2008, the company adopted SFAS No. 157 for the Company’s financial assets. SFAS No. 157 defines fair value, expands disclosure requirements and specifies a hierarchy of valuation techniques. The following are the levels of the hierarchy and a brief description of the type of valuation information (“inputs”) that qualifies a financial asset for each level:

	Input
Level Input:	Definition:
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

     When quoted prices in active markets for identical assets are available, the Company uses these quoted market prices to determine the fair value of financial assets and classify these assets as Level 1. In other cases where a quoted market price for identical assets in an active market is either not available or not observable, the Company obtains the fair value from a third party vendor that uses pricing models, such as matrix pricing, to calculate fair value. These financial assets would then be classified as Level 2. In the event quoted market prices were not available, the Company would determine fair value using broker quotes or an internal analysis of each investment’s financial statements and cash flow projections. In these instances, financial assets would be classified based upon the lowest level of input that is significant to the valuation. Thus, financial assets might be classified in Level 3 even though there could be some significant inputs that may be readily available.

     The following table summarizes fair value measurements by level at March 31, 2008 for assets measured at fair value on a recurring basis (in thousands):

	Level 1		Level 2		Level 3		Total
Investment securities: available for sale	$	—	$	40,228	$	—	$	40,228
Total	$	—	$	40,228	$	—	$	40,228

     (5) Medical Liabilities

     The Company’s medical liabilities at March 31, 2008 and December 31, 2007 consisted of the following (in thousands):

	March 31,		December 31,
	2008		2007
Medicare medical liabilities	$	129,066	$	116,048
Commercial medical liabilities		995		3,415
Pharmacy accounts payable		54,204		35,047
Total	$	184,265	$	154,510

7

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (6) Medicare Part D

     Total Part D related liabilities (excluding medical claims payable) of $104,594 at December 31, 2007 all related to the 2007 CMS plan year. The Company’s Part D related assets and liabilities (excluding medical claims payable) at March 31, 2008 were as follows (in thousands):

	Related to the		Related to the
	2007 plan year		2008 plan year		Total
Non-current assets:
Risk corridor receivable from CMS	$	—	$	14,779	$	14,779
Current liabilities:
Funds held for the benefit of members	$	83,912	$	19,855	$	103,767
Risk corridor payable to CMS		22,660		—		22,660
Total Part D liabilities (excluding medical claims payable)	$	106,572	$	19,855	$	126,427

     Balances associated with risk corridor amounts are expected to be settled in the fourth quarter of the year following the year to which they relate.

     (7) Stock-Based Compensation

Stock Options

     The Company granted nonqualified options to purchase 417,564 shares of common stock pursuant to the 2006 Equity Incentive Plan during the three months ended March 31, 2008, and options for the purchase of 3,549,281 shares of common stock were outstanding under this plan at March 31, 2008. The outstanding options vest and become exercisable based on time, generally over a four-year period, and expire ten years from their grant dates. Upon exercise, options are settled with authorized but unissued Company common stock or treasury shares.

     The fair value for all options granted during the three months ended March 31, 2008 and 2007 was determined on the date of grant and was estimated using the Black-Scholes option-pricing model with the following assumptions:

	Three Months Ended
	March 31,
	2008	2007
Expected dividend yield	0.0%	0.0%
Expected volatility	36.2%	45.0%
Expected term	5 years	5 years
Risk-free interest rates	2.93%	4.48-4.84%

     The weighted average fair value of stock options granted during the three months ended March 31, 2008 and 2007 was $7.13 and $10.00, respectively. Both the cash proceeds and the actual tax benefit realized from stock options exercised during the three months ended March 31, 2008 were nominal.

     Total compensation expense related to nonvested options not yet recognized was $16.6 million at March 31, 2008. The Company expects to recognize this compensation expense over a weighted average period of 2.5 years.

8

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

Restricted Stock

     During the three months ended March 31, 2008, the Company granted 108,895 shares of restricted stock to employees pursuant to the 2006 Equity Incentive Plan, all of which were outstanding at March 31, 2008. The restrictions relating to the restricted stock awards made in the current period lapse as follows: 50% of the shares upon the second anniversary of the grant date and 25% on both the third and fourth anniversaries of the grant date.

     Total compensation expense related to nonvested restricted stock awards not yet recognized, including awards made in previous periods, was $2.5 million at March 31, 2008. The Company expects to recognize this compensation expense over a weighted average period of approximately 2.9 years. Nonvested restricted stock at March 31, 2008 totaled 706,981 shares.

Stock-based Compensation

     Stock-based compensation is included in selling, general and administrative expense. Stock-based compensation for the three months ended March 31, 2008 and 2007 consisted of the following (in millions):

					Total
	Compensation Expense Related To:				Compensation
	Restricted Stock		Stock Options		Expense
Three months ended March 31, 2008	$	0.3	$	2.1	$	2.4
Three months ended March 31, 2007		0.2		1.9		2.1

Stock Repurchase Program

     In June 2007, the Company’s Board of Directors authorized a stock repurchase program to buy back up to $50.0 million of the Company’s common stock over the subsequent 12 months. The program authorizes purchases of common stock from time to time in either the open market or through private transactions, in accordance with SEC and other applicable legal requirements. The timing, prices, and sizes of purchases depends upon prevailing stock prices, general economic and market conditions, and other considerations. Funds for the repurchase of shares have, and are expected to, come primarily from unrestricted cash on hand and unrestricted cash generated from operations. The repurchase program does not obligate the Company to acquire any particular amount of common stock and the repurchase program may be suspended at any time at the Company’s discretion. As of March 31, 2008 the Company had repurchased 1,171,500 shares of its common stock under the program in open market transactions for approximately $20.6 million, at an average cost of $17.63, and had approximately $29.4 million in remaining repurchase authority under the program.

9

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (8) Net Income Per Common Share

     The following table presents the calculation of the Company’s net income per common share available to common stockholders — basic and diluted (in thousands, except share data):

	Three Months Ended
	March 31,
	2008		2007
Numerator:
Net income	$	21,058	$	14,090
Denominator:
Weighted average common shares outstanding — basic		56,861,343		57,233,712
Dilutive effect of stock options		86,970		87,147
Dilutive effect of unvested director shares		14,208		9,506
Weighted average common shares outstanding — diluted		56,962,521		57,330,365
Net income per common share:
Basic	$	0.37	$	0.25
Diluted	$	0.37	$	0.25

     Diluted earnings per share (“EPS”) reflects the potential dilution that could occur if stock options or other share-based awards were exercised or converted into common stock. The dilutive effect is computed using the treasury stock method, which assumes all share-based awards are exercised and the hypothetical proceeds from exercise are used by the Company to purchase common stock at the average market price during the period. The incremental shares (difference between shares assumed to be issued versus purchased), to the extent they would have been dilutive, are included in the denominator of the diluted EPS calculation. Options on 3.8 million shares and 2.7 million shares were antidilutive and therefore excluded from the computation of diluted earnings per share for the three months ended March 31, 2008 and 2007, respectively.

     (9) Intangible Assets

     A breakdown of the identifiable intangible assets, their assigned value and accumulated amortization at March 31, 2008 is as follows (in thousands):

	Gross Carrying		Accumulated
	Amount		Amortization		Net
Trade name	$	24,500	$	—	$	24,500
Noncompete agreements		800		493		307
Provider network		133,800		5,683		128,117
Medicare member network		92,128		15,471		76,657
Management contract right		1,554		285		1,269
	$	252,782	$	21,932	$	230,850

     Amortization expense on identifiable intangible assets for each of the quarters ended March 31, 2008 and 2007 was approximately $5.0 million and $1.9 million, respectively.

10

HEALTHSPRING, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

     (10) Comprehensive Income

     The following table presents details supporting the determination of comprehensive income for the three months ended March 31, 2008 and 2007:

	Three Months Ended
	March 31,
	2008		2007
Net income	$	21,058	$	14,090
Net unrealized investment gains on available for sale investment securities, net of tax		243		—
Comprehensive income, net of tax	$	21,301	$	14,090

11

Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations

     You should read the following discussion and analysis in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report and our audited consolidated financial statements and the notes thereto for the year ended December 31, 2007, appearing in our Annual Report on Form 10-K that was filed with the Securities and Exchange Commission (“SEC”) on February 29, 2008 (the “2007 Form 10-K”). Statements contained in this Quarterly Report on Form 10-Q that are not historical fact are forward-looking statements that the company intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Statements that are predictive in nature, that depend on or refer to future events or conditions, or that include words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” and similar expressions are forward-looking statements. The company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. In evaluating any forward-looking statement, you should specifically consider the information set forth under the captions “Special Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors” in the 2007 Form 10-K and the information set forth under “Cautionary Statement Regarding Forward-Looking Statements” in our earnings and other press releases, as well as other cautionary statements contained elsewhere in this report, including the matters discussed in “Critical Accounting Policies and Estimates” and Part II, Item 1A: Risk Factors below. We undertake no obligation beyond that required by law to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect.

Overview

General

     HealthSpring, Inc. (the “company” or “HealthSpring”) is a managed care organization whose primary focus is Medicare, the federal government-sponsored health insurance program for U.S. citizens aged 65 and older, qualifying disabled persons, and persons suffering from end-stage renal disease.

     We operate Medicare Advantage plans in Alabama, Florida, Illinois, Mississippi, Tennessee, and Texas and offer Medicare Part D prescription drug plans to persons in all 50 states. We sometimes refer to our Medicare Advantage plans (including plans providing prescription drug benefits, or “MA-PD”) collectively as “Medicare Advantage” plans and our stand-alone prescription drug plan as our “PDP.” For purposes of additional analysis, the company separately provides membership and certain financial information, including premium revenue and medical expense, for our Medicare Advantage (including MA-PD) and PDP plans. Although we concentrate on Medicare plans, we also utilize our infrastructure and provider networks in Alabama and Tennessee to offer commercial health plans to employer groups.

     The results of our newly-acquired Leon Medical Centers Health Plans (“LMC Health Plans”) are included in our results from October 1, 2007, the date of acquisition by the company.

12

Basis of Presentation

     The consolidated results of operations include the accounts of HealthSpring and its subsidiaries.

Results of Operations

     The following tables set forth the consolidated statements of income data expressed in dollars (in thousands) and as a percentage of total revenue for each period indicated.

	Three Months Ended March 31,
	2008					2007
Revenue:
Premium:
Medicare	$	538,553		97.5	%	$	331,780		93.1	%
Commercial		2,337		0.4			13,240		3.7
Total premium revenue		540,890		97.9			345,020		96.8
Management and other fees		6,907		1.2			6,049		1.7
Investment income		4,811		0.9			5,248		1.5
Total revenue		552,608		100.0			356,317		100.0
Operating expenses:
Medical expense:
Medicare		442,159		80.0			273,640		76.8
Commercial		2,023		0.4			10,055		2.8
Total medical expense		444,182		80.4			283,695		79.6
Selling, general and administrative		62,899		11.4			47,506		13.3
Depreciation and amortization		7,248		1.3			2,948		0.9
Interest expense		5,404		1.0			115		—
Total operating expenses		519,733		94.1			334,264		93.8
Income before equity in earnings of unconsolidated affiliate and income taxes		32,875		5.9			22,053		6.2
Equity in earnings of unconsolidated affiliate		101		—			21		—
Income before income taxes		32,976		5.9			22,074		6.2
Income tax expense		(11,918	)	(2.1	)		(7,984	)	(2.2	)
Net income	$	21,058		3.8	%	$	14,090		4.0	%

13

Membership

     Our primary source of revenue is monthly premium payments we receive based on membership enrolled in our managed care plans. The following table summarizes our Medicare Advantage (including MA-PD), stand-alone PDP, and commercial plan membership as of the dates indicated. Membership for Florida-based LMC Health Plans is reflected in our March 31, 2008 and December 31, 2007 results but not in our March 31, 2007 results. LMC Health Plans has no PDP or commercial membership.

	March 31,		December 31,		March 31,
	2008		2007		2007
Medicare Advantage Membership
Tennessee		49,174		50,510		48,309
Texas		38,357		36,661		35,810
Alabama		28,045		30,600		29,078
Florida(1)		26,681		25,946		—	(2)
Illinois		8,735		8,639		7,614
Mississippi		1,535		841		716
Total		152,527		153,197		121,527
Medicare PDP Membership		258,012		139,212		110,692
Commercial Membership
Tennessee		1,402		11,046		14,374
Alabama		1,028		755		744
Total		2,430		11,801		15,118

(1)	The company acquired LMC Health Plans on October 1, 2007. As of the acquisition date, LMC Health Plans had approximately 25,800 Medicare Advantage members.
(2)	LMC Health Plans’ Medicare Advantage membership was 24,974 at March 31, 2007.

     Medicare Advantage. Our Medicare Advantage membership increased by 25.5% to 152,527 members at March 31, 2008 as compared to 121,527 members at March 31, 2007, primarily as a result of membership resulting from the acquisition of LMC Health Plans. As anticipated, our Alabama membership decreased slightly in the current quarter compared to membership at both December 31, 2007 and March 31, 2007 as a result of the Company exiting certain counties. Similarly, the Tennessee market experienced slight and anticipated decreases in membership in the current quarter compared to December 31, 2007 as a result of discontinuing certain products. We anticipate incremental membership growth throughout the remainder of 2008 through the offering of products to the dual-eligible population, who are not restricted by the lock-in rules, including our new OptimaCare product, our special needs plan (“SNP”), focused on the treatment of individuals with chronic conditions such as diabetes, hypertension and hyperlipidemia.

     PDP. PDP membership increased by 133.1% to 258,012 members at March 31, 2008 as compared to 110,692 at March 31, 2007, primarily as a result of additional auto-assignment of members in the California and New York regions. We do not actively market our PDPs and have relied primarily on CMS auto-assignments of dual-eligible beneficiaries for membership. We continue to receive assignments or otherwise enroll dual-eligible beneficiaries in our PDP plans during lock-in.

14

     Commercial. Our commercial HMO membership declined from 15,118 members at March 31, 2007 to 2,430 members at March 31, 2008, primarily as a result of the anticipated non-renewal of coverage by several large employer groups in Tennessee.

Risk Adjustment Payments

     Our Medicare premium revenue is subject to periodic adjustment under CMS’s risk adjustment payment methodology based on the health risk of our members. Under the risk adjustment payment methodology, managed care plans must capture, collect, and report diagnosis code information to CMS. After reviewing the respective submissions, CMS establishes the payments to Medicare plans generally at the beginning of the calendar year, and then adjusts premium levels, typically on two separate occasions, on a retroactive basis. The first retroactive risk premium adjustment for a given year generally occurs during the third quarter of such year. This initial settlement (the “Initial CMS Settlement”) represents the updating of risk scores for the current year based on the prior year’s dates of service. CMS then issues a final retroactive risk premium adjustment settlement for that year in the following year (the “Final CMS Settlement”). In the first quarter of 2007, we began estimating and recording on a monthly basis the Initial CMS Settlement, as we concluded we had the ability to reasonably estimate such amounts. Similarly, in the fourth quarter of 2007 the company began accruing for the estimated 2007 Final CMS Settlement based on risk score data available at that time. During the 2008 first quarter, the company updated its estimated final payment amounts for 2007 based on its evaluation of additional diagnosis code information reported to CMS in 2008. This change in estimate resulted in recording an additional $12.0 million of Medicare premium revenue and $3.8 million of related medical expense for risk sharing with providers in the 2008 first quarter.

     As of January 2008, we began estimating and recording on a monthly basis both the Initial CMS Settlement and the Final CMS Settlement for the 2008 CMS plan year. Results of operations for the 2007 first quarter do not include any premiums for estimated final CMS settlements. All such estimated amounts are periodically updated as necessary as additional diagnosis code information is reported to CMS and adjusted to actual amounts when the ultimate adjustment settlements are either received from CMS or we receive notification from CMS of such settlement amounts.

Comparison of the Three-Month Period Ended March 31, 2008 to the Three-Month Period Ended March 31, 2007

Revenue

     Total revenue was $552.6 million in the three-month period ended March 31, 2008 as compared with $356.3 million for the same period in 2007, representing an increase of $196.3 million, or 55.1%. The components of revenue were as follows:

     Premium Revenue: Total premium revenue for the three months ended March 31, 2008 was $540.9 million as compared with $345.0 million in the same period in 2007, representing an increase of $195.9 million, or 56.8%. The components of premium revenue and the primary reasons for changes were as follows:

Medicare Advantage: Medicare Advantage (including MA-PD) premiums were $459.3 million for the three months ended March 31, 2008 versus $298.8 million in the first quarter of 2007, representing an increase of $160.5 million, or 53.7%. The increase in Medicare Advantage premiums in 2008 is attributable to the inclusion of LMC Health Plans’ results and increases in both membership (which we measure in member months) and per member per month, or “PMPM,” premium rates. In addition, the 2008 first quarter results include $12.0 million of additional Medicare Advantage premium revenue for 2007 final retroactive premium settlements as a result of the company updating its estimated premium amounts for 2007 (see “Risk Adjustment Payments” above). Member months increased 27.0% to 456,150 for the 2008 first quarter from 359,059 for the comparable 2007 quarter. PMPM premiums for the 2008 first quarter were $980.56, as adjusted to exclude the additional 2007 final retroactive risk premiums recorded in the 2008 first quarter, and

15

increased 17.8% compared to the 2007 first quarter. The PMPM premium increase in the current quarter is primarily the result of rate increases in the 2008 first quarter, the inclusion of $12.0 million of 2007 risk settlement premiums discussed above, and the inclusion of LMC Health Plans’ results in the current quarter, as LMC Health Plans has historically acquired higher PMPM premiums than our other markets.

PDP: PDP premiums (after risk corridor adjustments) were $79.2 million in the three months ended March 31, 2008 compared to $33.0 million in the same period of 2007, an increase of $46.2 million, or 140.5%. The increase in premiums for the 2008 first quarter is the result of increases in membership and PMPM premiums. Our average PMPM premiums (after risk corridor adjustments) increased 2.6% to $103.31 in the current quarter versus $100.68 during the 2007 quarter.

Commercial: Commercial premiums were $2.3 million in the three months ended March 31, 2008 as compared with $13.2 million in the 2007 comparable period, reflecting a decrease of $10.9 million, or 82.4%. The decrease was primarily attributable to the 81.4% decline in member months, primarily as a result of the non-renewal by several large employer groups in Tennessee.

     Fee Revenue. Fee revenue was $6.9 million in the first quarter of 2008 compared to $6.0 million for the first quarter of 2007, an increase of $0.9 million. The increase in the current period is attributable to higher PMPM premiums and management fees associated with new IPAs under contract with us since the 2007 first quarter.

     Investment Income. Investment income was $4.8 million for the first quarter of 2008 versus $5.2 million for the comparable period of 2007, reflecting a decrease of $0.4 million, or 8.3%. The decrease is attributable to a decrease in average invested and cash balances, which was primarily attributable to the use of unrestricted cash to fund a portion of the purchase price for the LMC Health Plans and to fund the repurchase of company stock, coupled with a lower average yield on these balances.

Medical Expense

     Medicare Advantage Medicare Advantage (including MA-PD) medical expense for the three months ended March 31, 2008 increased $122.8 million, or 50.6%, to $365.4 million from $242.6 million for the comparable period of 2007, primarily as a result of the inclusion of medical expense incurred by LMC Health Plans in 2008 and as a result of increased membership and utilization in our other health plans. For the three months ended March 31, 2008, the Medicare Advantage medical loss ratio, or “MLR,” was 79.6% versus 81.2% for the same period of 2007. The MLR improvement in the 2008 first quarter is primarily the result of higher PMPM premiums and the change in estimate for the 2007 Final CMS Settlement discussed previously (see “Risk Adjustment Payments” above), the latter of which had a favorable impact of 130 basis points on the 2008 first quarter MLR. The improvement in MLR during the 2008 first quarter would have been greater had it not been for more pronounced seasonality in the Part D component of our MA MLR caused by the expansion of Part D risk corridors.

     Under the Part D benefit design, a disproportionate amount of drug costs for MA-PD members are incurred in the first half of the year, which contributed unfavorably to the MLR in the first quarter of each period. Our Medicare Advantage medical expense calculated on a PMPM basis was $801.11 for the three months ended March 31, 2008, compared with $675.76 for the comparable 2007 quarter, reflecting an increase of 18.6%, primarily as a result of the inclusion of LMC Health Plans’ results in the current quarter, increased drug costs, and higher than anticipated inpatient utilization. LMC Health Plans incurs a substantially higher PMPM medical expense than our other plans. The Company believes that the higher inpatient utilization was attributable, in part, to the flu season.

     PDP. PDP medical expense for the three months ended March 31, 2008 increased $45.7 million to $76.7 million, compared to $31.0 million in the same period last year. PDP MLR for the 2008 first quarter was 96.8%, compared to 94.1% in the 2007 first quarter. The increase in PDP MLR for the current quarter was primarily a function of the expansion of the Part D risk corridors, increases in the cost of prescription

16

drugs, and different pharmacy utilization patterns in new markets, including a higher utilization of brand versus generic drugs, which was partially offset by the increase in PDP PMPM revenue in the 2008 period. Because of the Part D product benefit design, the company incurs prescription drug costs unevenly throughout the year, including a disproportionate amount of prescription drug costs in the first half of the year. In 2008, with the widening of the Part D risk corridors, the Company anticipates that the profitability of PDP operations will be more weighted toward the second half of the year than the Company has experienced in prior years.

     Commercial. Commercial medical expense decreased by $8.0 million, or 79.9%, to $2.0 million for the first quarter of 2008 as compared to $10.0 million for the same period of 2007. The decrease in the current quarter was attributable to the reduction in membership versus the prior year quarter.

Selling, General, and Administrative Expense

     Selling, general, and administrative expense, or “SG&A,” for the three months ended March 31, 2008 was $62.9 million as compared with $47.5 million for the same prior year period, an increase of $15.4 million, or 32.4%. The increase in the 2008 first quarter as compared to the same period of the prior year is the result of the inclusion of LMC Health Plans, personnel and other administrative costs increases in the current period, and costs related to PDP membership increases. As a percentage of revenue, SG&A expense was 11.4% for the three months ended March 31, 2008 compared to 13.3% in the prior year first quarter. The decrease in SG&A as a percentage of revenue in the current quarter was primarily the result of improved operating leverage and the inclusion of LMC Health Plans, which has historically operated at a substantially lower SG&A percentage than our company as a whole.

     Consistent with historical trends, the company expects the majority of its marketing expenses to be incurred in the first and fourth quarters of each year in connection with the annual Medicare enrollment cycle.

Depreciation and Amortization Expense

     Depreciation and amortization expense was $7.2 million in the three months ended March 31, 2008 as compared with $2.9 million in the same period of 2007, representing an increase of $4.3 million, or 145.9%. The increase in the current quarter was primarily the result of $3.3 million in amortization expense associated with intangible assets recorded as part of the acquisition of LMC Health Plans in October 2007 and incremental depreciation on property and equipment additions made in 2007 and 2008.

Interest Expense

     Interest expense was $5.4 million in the 2008 first quarter, compared with $0.1 million in the 2007 first quarter. Interest expense recognized in the 2008 period was the result of the company borrowing $300.0 million on October 1, 2007 in connection with the purchase of LMC Health Plans.

Income Tax Expense

     For the three months ended March 31, 2008, income tax expense was $11.9 million, reflecting an effective tax rate of 36.1%, versus $8.0 million, reflecting an effective tax rate of 36.2%, for the same period of 2007. The Company expects the effective tax rate for the full 2008 year will approximate 36.1%.

Liquidity and Capital Resources

     We finance our operations primarily through internally generated funds. All of our outstanding funded indebtedness was incurred in connection with the acquisition of the LMC Health Plans in October 2007. See “—Indebtedness” below.

     We generate cash primarily from premium revenue and our primary use of cash is the payment of medical and SG&A expenses. We anticipate that our current level of cash on hand, internally generated

17

cash flows, and borrowings available under our revolving credit facility will be sufficient to fund our working capital needs, our debt service, and anticipated capital expenditures over the next twelve months.

     The reported changes in cash and cash equivalents for the three-month period ended March 31, 2008, compared to the comparable period of 2007, were as follows:

	Three Months Ended
	March 31,
	2008			2007
	(in thousands)
Net cash provided by operating activities	$	14,010		$	102,407
Net cash provided by (used in) investing activities		25,094			(19,667	)
Net cash (used in) provided by financing activities		(2,848	)		52,760
Net increase in cash and cash equivalents	$	36,256		$	135,500

Cash Flows from Operating Activities

     Our primary sources of liquidity are cash flow provided by our operations, available cash on hand and our revolving credit facility. We generated cash from operating activities of $14.0 million during the three months ended March 31, 2008, compared to $102.4 million during the three months ended March 31, 2007. Cash flows from operations for the 2008 first quarter trailed net income for the quarter of $21.1 million primarily as a result of accruing revenue and expenses associated with CMS risk payments and accruing risk corridor revenue from CMS.

     Our reported cash flows are significantly influenced by the timing of the Medicare premium remittance from CMS, which is payable to us normally on the first day of each month. This payment is from time to time received in the month prior to the month of medical coverage. When this happens, we record the receipt in deferred revenue and recognize it as premium revenue in the month of medical coverage. In 2007, the April payments were received in March, which had the effect of increasing operating cash flows in that month with a corresponding decrease in April. Adjusting our operating cash flows in the first three months for the effect of the timing of this payment, our operating cash flows would have been as follows:

	Three Months Ended
	March 31,
	2008		2007
	(in thousands)
Net cash provided by operating activities, as reported	$	14,010	$	102,407
Timing effect of CMS payment		—		(109,693	)
Adjusted net cash provided by (used in) operating activities	$	14,010	$	(7,286	)

     The $21.3 million favorable variance in the adjusted cash flows from operations for the first three months of 2008 compared to the first three months of 2007 was primarily caused by the timing of claims payments and income tax payments in 2008 and lower incentive compensation payments and less commercial claims payments in 2008 as compared to 2007.

18

Cash Flows from Investing and Financing Activities

     For the three months ended March 31, 2008, the primary investing activities consisted of $1.9 million in property and equipment additions and $28.5 million in proceeds from the maturity of investment securities. The investing activity in the prior year period consisted primarily of $16.7 million used to purchase investments and $4.3 million in property and equipment additions. During the three months ended March 31, 2008, the company’s financing activities consisted primarily of $21.5 million of funds received in excess of funds withdrawn from CMS for the benefit of members and $20.6 million expended for the repurchase of company stock. The financing activity in the prior year period consisted primarily of $52.5 million of funds received in excess of funds withdrawn from CMS for the benefit of members. Funds from CMS received for the benefit of members are recorded as a liability on our balance sheet at March 31, 2008. We anticipate settling approximately $106.6 million of Part D related amounts relating to 2007 with CMS during the fourth quarter of 2008 as part of the final settlement of Part D payments for the 2007 plan year. We expect positive cash flows in the subsequent periods of 2008 for similar subsidies from CMS related to the 2008 Medicare year.

     During the first quarter of 2008, the company repurchased approximately 1.2 million shares in open market transactions at an average cost of $17.63 under the previously authorized $50.0 million stock repurchase program. All repurchases were made utilizing unrestricted cash on hand. No repurchases were made under the program prior to the first quarter of 2008. The company currently has approximately $29.4 million in remaining repurchase authority under the program.

Cash and Cash Equivalents

     At March 31, 2008, the company’s cash and cash equivalents were $360.3 million, $38.4 million of which was held at unregulated subsidiaries. Approximately $103.8 million of the cash balance relates to amounts held by the company for the benefit of its Part D members. We expect CMS to settle these 2007 amounts during the fourth quarter of this year.

Statutory Capital Requirements

     Our HMO subsidiaries are required to maintain satisfactory minimum net worth requirements established by their respective state departments of insurance. At March 31, 2008, our Texas (minimum $12.5 million; actual $52.1 million), Tennessee (minimum $14.8 million; actual $58.2 million), Florida (minimum $7.8 million; actual $17.5 million) and Alabama (minimum $1.1 million; actual $35.8 million) HMO subsidiaries were in compliance with statutory minimum net worth requirements. Notwithstanding the foregoing, the state departments of insurance can require our HMO subsidiaries to maintain minimum levels of statutory capital in excess of amounts required under the applicable state law if they determine that maintaining additional statutory capital is in the best interest of our members.

     The HMOs are restricted from making distributions without appropriate regulatory notifications and approvals or to the extent such distributions would put them out of compliance with statutory net worth requirements. At March 31, 2008, $396.8 million of our $435.2 million of cash, cash equivalents, investment securities and restricted investments were held by our HMO subsidiaries and subject to these dividend restrictions. Our Alabama HMO subsidiary distributed $5.0 million in cash to the parent company in the 2008 first quarter. Our Texas HMO subsidiary distributed $14.0 million to the parent company in April 2008.

19

Indebtedness

     Long-term debt at March 31, 2008 and December 31, 2007 consisted of the following (in thousands):

	March 31,			December 31,
	2008			2007
Senior secured term loan	$	292,500		$	296,250
Less: current portion of long-term debt		(22,500	)		(18,750	)
Long-term debt less current portion	$	270,000		$	277,500

     In connection with funding the acquisition of LMC Health Plans, on October 1, 2007, we entered into agreements with respect to a $400.0 million, five-year credit facility, (collectively the “Credit Agreement”) which, subject to the terms and conditions set forth therein, provides for $300.0 million in term loans and a $100.0 million revolving credit facility. The $100.0 million revolving credit facility, which is available for working capital and general corporate purposes including capital expenditures and permitted acquisitions, is undrawn as of the date of this report.

     Borrowings under the Credit Agreement accrue interest on the basis of either a base rate or a LIBOR rate plus, in each case, an applicable margin (initially 250 basis points for LIBOR advances) depending on our debt-to-EBITDA leverage ratio. The weighted average interest rate incurred on borrowings under the Credit Agreement during the three month period ended March 31, 2008 was 6.2%. We also pay commitment fees on the unfunded portion of the lenders’ commitments under the revolving credit facility, the amounts of which will also depend on our leverage ratio. The Credit Agreement matures, the commitments thereunder terminate, and all amounts then outstanding thereunder are payable on October 1, 2012.

     The net proceeds from certain asset sales, casualty/condemnation events, and incurrences of indebtedness (subject, in the cases of asset sales and casualty/condemnation events, to certain reinvestment rights), and a portion of the net proceeds from equity issuances and our excess cash flow, are required to be used to make prepayments in respect of loans outstanding under the Credit Agreement.

     The Credit Agreement contains conditions precedent to extensions of credit and representations, warranties, and covenants, including financial covenants, customary for transactions of this type. The Credit Agreement also contains customary events of default as well as restrictions on undertaking certain specified corporate actions. If an event of default occurs that is not otherwise waived or cured, the lenders may terminate their obligations to make loans and other extensions of credit under the Credit Agreement and the obligations of the issuing banks to issue letters of credit and may declare the loans outstanding under the Credit Agreement to be due and payable. The company believes it is currently in compliance with its financial and other covenants under the Credit Agreement.

Off-Balance Sheet Arrangements

     At March 31, 2008, we did not have any off-balance sheet arrangement requiring disclosure.

Commitments and Contingencies

     We did not experience any material changes to contractual obligations outside the ordinary course of business during the three months ended March 31, 2008.

Critical Accounting Policies and Estimates

     The preparation of our consolidated financial statements requires our management to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. Changes in estimates are

20

recorded if and when better information becomes available. Actual results could differ significantly from those estimates under different assumptions and conditions. The following provides a summary of our accounting policies and estimates relating to medical expense and the related medical claims liability and premium revenue recognition. For a more complete discussion of these and other critical accounting policies and estimates of the company, see our 2007 Form 10-K.

Medical Expense and Medical Claims Liability

     Medical expense is recognized in the period in which services are provided and includes an estimate of the cost of medical expense that has been incurred but not yet reported, or IBNR. Medical expense includes claim payments, capitation payments, and pharmacy costs, net of rebates, as well as estimates of future payments of claims incurred, net of reinsurance. Capitation payments represent monthly contractual fees disbursed to physicians and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members’ prescription drug benefits, net of rebates from drug manufacturers. Rebates are recognized when earned, according to the contractual arrangements with the respective vendors. Premiums we pay to reinsurers are reported as medical expenses and related reinsurance recoveries are reported as deductions from medical expenses.

     The IBNR component of total medical claims liability is based on our historical claims data, current enrollment, health service utilization statistics, and other related information. Estimating IBNR is complex and involves a significant amount of judgment. Accordingly, it represents our most critical accounting estimate. Changes in this estimate can materially affect, either favorably or unfavorably, our consolidated operating results and overall financial position.

     Our policy is to record each plan’s best estimate of medical expense IBNR. Using actuarial models, we calculate a minimum amount and maximum amount of the IBNR component. To most accurately determine the best estimate, our actuaries determine the point estimate within their minimum and maximum range by similar medical expense categories within lines of business. The medical expense categories we use are: in-patient facility, outpatient facility, all professional expense, and pharmacy. The lines of business are Medicare and commercial. The development of the IBNR estimate generally considers favorable and unfavorable prior period developments and uses standard actuarial developmental methodologies, including completion factors, claims trends, and provisions for adverse claims developments.

     The completion and claims trend factors are the most significant factors impacting the IBNR estimate. The following table illustrates the sensitivity of these factors and the impact on our operating results caused by changes in these factors that management believes are reasonably likely based on our historical experience and March 31, 2008 data:

Completion Factor (a)		Claims Trend Factor (b)
	Increase		Increase
	(Decrease)		(Decrease)
Increase	in Medical	Increase	in Medical
(Decrease)	Claims	(Decrease)	Claims
in Factor	Liability	in Factor	Liability
(Dollars in thousands)
3%	$(3,790)	(3)%	$(2,004)
2	(2,555)	(2)	(1,334)
1	(1,292)	(1)	(666)
(1)	1,323	1	664

(a) Impact due to change in completion factor for the most recent three months. Completion factors indicate how complete claims paid to date are in relation to estimates for a given reporting period. Accordingly, an increase in completion factor results in a decrease in the remaining estimated liability for medical claims.

21

(b) Impact due to change in annualized medical cost trends used to estimate PMPM costs for the most recent three months.

     Our provision for adverse claims development as of the last three year ends has been relatively consistent. Primarily as a result of the growth and stabilizing trends experienced in our Medicare business, continued favorable development of prior period IBNR estimates, and the continued decline in our commercial line of business, the provision for adverse claims development has become a relatively insignificant component of medical claims liability.

     Our medical claims liability also considers premium deficiency situations and evaluates the necessity for additional related liabilities. There were no material premium deficiency accruals at March 31, 2008.

Premium Revenue Recognition

     We generate revenues primarily from premiums we receive from CMS, and to a lesser extent our commercial customers, to provide healthcare benefits to our members. We receive premium payments on a PMPM basis from CMS to provide healthcare benefits to our Medicare members, which premiums are fixed on an annual basis by contracts with CMS. Although the amount we receive from CMS for each member is fixed, the amount varies among Medicare plans according to, among other things, demographics, geographic location, age, gender, and the relative risk score of the plan’s membership.

     We generally receive premiums on a monthly basis in advance of providing services. Premiums collected in advance are deferred and reported as deferred revenue. We recognize premium revenue during the period in which we are obligated to provide services to our members. Any amounts that have not been received are recorded on the balance sheet as accounts receivable.

     Our Medicare premium revenue is subject to periodic adjustment under what is referred to as CMS’s risk adjustment payment methodology based on the health risk of our members. Risk adjustment uses health status indicators to improve the accuracy of payments and establish incentives for plans to enroll and treat less healthy Medicare beneficiaries.

     Under the risk adjustment payment methodology, managed care plans must capture, collect, and report diagnosis code information to CMS. After reviewing the respective submissions, CMS establishes the payments to Medicare plans generally at the beginning of the calendar year, and then adjusts premium levels on two separate occasions on a retroactive basis. The first retroactive risk premium adjustment for a given fiscal year generally occurs during the third quarter of such fiscal year. This initial settlement (the “Initial CMS Settlement”) represents the updating of risk scores for the current year based on the prior year’s dates of service. CMS then issues a final retroactive risk premium adjustment settlement for that fiscal year in the following year (the “Final CMS Settlement”). Prior to 2007, we were unable to estimate the impact of either of these risk adjustment settlements, and as such recorded them upon notification from CMS of such amounts. In the first quarter of 2007, we began estimating and recording on a monthly basis the Initial CMS Settlement, as we concluded we had the ability to reasonably estimate such amounts. Similarly, in the fourth quarter of 2007, we estimated and recorded the Final CMS Settlement for 2007 (based on risk score data available at that time), as we concluded such amounts were estimable. As such, the first quarter of 2007 does not include any estimated premiums related to Final CMS Settlements. During the 2008 first quarter the company updated its estimated final payment amounts for 2007 based on its evaluation of additional diagnosis code information reported to CMS in 2008.

     As of January 2008, we estimate and record on a monthly basis both the Initial CMS Settlement and the Final CMS Settlement for the 2008 CMS plan year. All such estimated amounts are periodically updated as necessary as additional diagnosis code information is reported to CMS and adjusted to actual amounts when the ultimate adjustment settlements are either received from CMS or the company receives notification from CMS of such settlement amounts.

22

Recently Issued Accounting Pronouncements

     In September 2006, the Financial Accounting Standards Board (“FASB”) issued Statement of Financial Accounting Standard (“SFAS”) No. 157, “Fair Value Measurements” (“SFAS No. 157”). SFAS No. 157 establishes a common definition for fair value to be applied to U.S. GAAP requiring use of fair value, establishes a framework for measuring fair value, and expands disclosure about such fair value measurements. SFAS No. 157 is effective for financial assets and financial liabilities for fiscal years beginning after November 15, 2007. Issued in February 2008, FSP 157-1 “Application of FASB Statement No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements That Address Fair Value Measurements for Purposes of Lease Classification or Measurement under Statement 13” removed leasing transactions accounted for under Statement 13 and related guidance from the scope of SFAS No. 157. FSP 157-2 “Partial Deferral of the Effective Date of Statement 157” (“FSP 157-2”), deferred the effective date of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities to fiscal years beginning after November 15, 2008.

     The implementation of SFAS No. 157 for financial assets and financial liabilities, effective January 1, 2008, did not have a material impact on our consolidated financial position and results of operations. The company is currently assessing the impact of SFAS No. 157 for nonfinancial assets and nonfinancial liabilities on its consolidated financial position and results of operations.

     In February 2007, the FASB issued SFAS No. 159, “The Fair Value Option for Financial Assets and Financial Liabilities” (“SFAS No. 159”). SFAS No. 159, which amends SFAS No. 115, “Accounting for Certain Investments in Debt and Equity Securities,” allows certain financial assets and liabilities to be recognized, at the company’s election, at fair market value, with any gains or losses for the period recorded in the statement of income. SFAS No. 159 included available-for-sale securities in the assets eligible for this treatment. Currently, the company records the gains or losses for the period in the statement of comprehensive income and in the equity section of the balance sheet. SFAS No. 159 is effective for fiscal years beginning after November 15, 2007, and interim periods in those fiscal years. The company adopted SFAS No. 159 effective January 1, 2008. The company, at this time, has not elected to recognize any gains or losses for its available-for-sale securities in the statement of income. Accordingly, there was no impact on the company’s financial position or results of operations as a result of adopting the new standard.

     On December 4, 2007, the FASB issued SFAS No. 141 (Revised 2007), “Business Combinations”, or “SFAS No. 141(R).” SFAS No. 141(R) will significantly change the accounting for business combinations. Under SFAS No. 141(R), an acquiring entity will be required to recognize all the assets acquired and liabilities assumed in a transaction at the acquisition-date fair value with limited exceptions. SFAS No. 141(R) also includes a substantial number of new disclosure requirements. SFAS No. 141(R) applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, which is the year beginning January 1, 2009 for us. We are currently evaluating the impact that SFAS No. 141(R) will have on our financial statements.

     In December 2007, the Financial Accounting Standards Board (“FASB”) issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements — an amendment of ARB No. 51” (“SFAS No. 160”). This statement improves the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards that require all entities to report noncontrolling (minority) interests in subsidiaries in the same way, that is, as equity in the consolidated financial statements. Additionally, SFAS No. 160 requires that entities provide sufficient disclosures that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. SFAS No. 160 affects those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary. SFAS No. 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. Early adoption is prohibited. The adoption of this statement is not expected to have a material effect on the company’s financial statements

23

Item 3: Quantitative and Qualitative Disclosures About Market Risk

     As of March 31, 2008, no material changes had occurred in our exposures to interest rate risk since the information previously reported as of year end under the caption “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our 2007 Form 10-K, other than an increase in our cash and cash equivalents in the ordinary course of business, the sensitivity of which to changes in interest rates we would not consider material to our business.

     The Company currently has no material investments in securities that are collateralized by subprime mortgages.

Item 4: Controls and Procedures

     Our senior management carried out the evaluation required by Rule 13a-15 under the Exchange Act, under the supervision and with the participation of our President and Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15 and 15d-15 under the Exchange Act (“Disclosure Controls”). Based on the evaluation, our senior management, including our CEO and CFO, concluded that, subject to the limitations noted herein, as of March 31, 2008, our Disclosure Controls are effective in timely alerting them to material information required to be included in our reports filed with the SEC.

     There has been no change in our internal control over financial reporting identified in connection with the evaluation that occurred during the quarter ended March 31, 2008 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting

     Our management, including our CEO and CFO, does not expect that our Disclosure Controls and internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.

     The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.

24

Part II — OTHER INFORMATION

Item 1: Legal Proceedings

     We are not currently involved in any pending legal proceedings that we believe are material. We are, however, involved from time to time in routine legal matters and other claims incidental to our business, including employment-related claims, claims relating to our health plans’ contractual relationships with providers and members, and claims relating to marketing practices of sales agents and agencies that are employed by, or independent contractors to, our health plans. Although there can be no assurances, the Company believes that the resolution of existing routine matters and other incidental claims will not have a material adverse effect on our financial condition or results of operations.

Item 1A: Risk Factors

     In addition to the other information set forth in this report, you should consider carefully the risks and uncertainties previously reported and described under the captions “Part I — Item 1A. Risk Factors” in the 2007 Form 10-K, the occurrence of any of which could materially and adversely affect our business, prospects, financial condition, and operating results. The risks previously reported and described in our 2007 Form 10-K are not the only risks facing our business. Additional risks and uncertainties not currently known to us or that we currently consider to be immaterial also could materially and adversely affect our business, prospects, financial condition, and operating results.

     The following risk factor is updated from our 2007 Form 10-K to reflect updated or additional risks and uncertainties.

CMS’s Risk Adjustment Payment System and Budget Neutrality Factors Make Our Revenue and Profitability Difficult to Predict and Could Result In Material Retroactive Adjustments to Our Results of Operations.

     CMS has implemented a risk adjustment payment system for Medicare health plans to improve the accuracy of payments and establish incentives for Medicare plans to enroll and treat less healthy Medicare beneficiaries. CMS’s risk adjustment model bases a portion of the total CMS reimbursement payments on various clinical and demographic factors including hospital inpatient diagnoses, diagnosis data from ambulatory treatment settings, including hospital outpatient facilities and physician visits, gender, age, and Medicaid eligibility. CMS requires that all managed care companies capture, collect, and report the necessary diagnosis code information to CMS. Following initial phase-in from 2003 to 2006, in 2007 risk adjustment payments began to account for 100% of Medicare health plan payments. Because 100% of Medical Advantage premiums are now risk-based, it is difficult to predict with certainty our future revenue or profitability.

     In addition, CMS establishes premium payments to Medicare plans generally at the beginning of the calendar year and then adjusts premium levels on two separate occasions during the year on a retroactive basis. The first such adjustment updates the risk scores for the current year based on prior year’s dates of service. The second such adjustment is a final retroactive risk premium settlement for the prior year. As of January 2008, the company is estimating and recording on a monthly basis both such adjustments. As a result of the variability of factors, including plan risk scores, that determine such estimations, the actual amount of CMS’s retroactive payment could be materially more or less than our estimates. Consequently, our estimate of our plans’ risk scores for any period, and our accrual of premiums related thereto, may result in favorable or unfavorable adjustments to our Medicare premium revenue and, accordingly, our profitability.

     In February 2008, CMS published preliminary results of a study designed to assess the degree of coding pattern differences between members in Medicare fee-for-service and Medicare Advantage and the extent to which any such differences could be appropriately addressed by an adjustment to risk scores. CMS’s study of risk scores for Medicare populations from 2004 through 2006 found that Medicare Advantage member risk

25

scores increased substantially more than the risk scores for the general Medicare fee-for-service population. As a result of the study, CMS proposed a negative adjustment to the risk scores of enrollees, and a corresponding decrease in premiums, in Medicare Advantage plans for which the differences between a plan’s increase in risk scores for “stayers” (in CMS parlance) and the increase in fee-for-service risk scores was two or more times the industry average. CMS’s final announcement of 2009 capitation rates in early April 2008 withdrew the proposed adjustment based, in part, on comments opposing the adjustment. CMS indicated in its announcement that it hoped to be in a position to reach a more definitive conclusion on these matters prior to the announcement of 2010 capitation rates. If adjustments are proposed at that time that are similar to CMS’s withdrawn proposal regarding adjustments to the 2009 capitation rates, there can be no assurance that such proposal, if implemented, will not have a material adverse impact on one or more of the company’s health plans.

     Payments to Medicare Advantage plans are also adjusted by a “budget neutrality” factor that was implemented in 2003 by Congress and CMS to prevent health plan payments from being reduced overall while, at the same time, directing risk adjusted payments to plans with more chronically ill enrollees. In general, this adjustment favorably impacted payments to Medicare Advantage plans. In February 2006, the President signed legislation that reduced federal funding for Medicare Advantage plans by approximately $6.5 billion over five years. Among other changes, the legislation provided for an accelerated phase-out of budget neutrality for risk adjusted payments made to Medicare Advantage plans. These legislative changes have the effect of reducing payments to Medicare Advantage plans in general. Consequently, our plans’ premiums will be reduced over the phase-out period unless our risk scores increase in a manner sufficient, when considered together with inflation-related increases in rates, to offset the elimination of this adjustment. Although our plans’ risk scores have increased historically, there is no assurance that the increases will continue or, if they do, that they will be large enough to offset the elimination of this adjustment.

Item 2: Unregistered Sales of Equity Securities and Use of Proceeds

     Issuer Purchases of Equity Securities

     During the quarter ended March 31, 2008 the Company repurchased the following shares of its common stock:

ISSUER PURCHASES OF EQUITY SECURITIES

							Approximate Dollar
					Total Number of		Value
	Total				Shares Purchased as		of Shares that May
	Number of		Average		Part of Publicly		Yet Be
	Shares		Price Paid		Announced Plans		Purchased Under the
Period	Purchased		per Share		or Programs		Plans or Programs
1/1/08 – 1/31/08		1,125	$	0.20		—		—
2/1/08 – 2/29/08		697,500		18.38		697,500		—
3/1/08 – 3/31/08		474,000		16.54		474,000		—
Total		1,172,625	$	17.62		1,171,500	$	29,400,000

     In January 2008, the Company purchased 1,125 shares pursuant to the terms of a restricted stock purchase agreement between a former employee and the Company. The shares were repurchased at the Company’s option at a price of $.20 per share, the former employee’s cost for such shares.

     In June 2007, the Company’s Board of Directors authorized a stock repurchase program to repurchase up to $50.0 million of the Company’s common stock over the succeeding 12 months. The program is intended to be implemented through purchases made from time to time in either the open market or through privately negotiated transactions, in accordance with SEC and other applicable legal requirements. The timing, prices, and sizes of purchases will depend upon prevailing stock prices, general economic and market conditions, and other factors. Funds for the repurchase of shares have, and are expected to, come primarily

26

from unrestricted cash on hand and unrestricted cash generated from operations. The repurchase program does not obligate the Company to acquire any particular amount of common stock and the repurchase program may be suspended at any time at the Company’s discretion. As of March 31, 2008 the Company had spent approximately $20.6 million to purchase 1,171,500 shares of common stock under the program.

     Our ability to purchase common stock and to pay cash dividends is limited by our credit agreement As a holding company, our ability to repurchase common stock and to pay cash dividends are dependent on the availability of cash dividends from our regulated HMO subsidiaries, which are restricted by the laws of the states in which we operate and CMS, as well as limitations under our credit agreement.

Item 3: Defaults Upon Senior Securities

     Inapplicable.

Item 4: Submission of Matters to a Vote of Security Holders

     Inapplicable.

Item 5: Other Information

     Inapplicable.

27

Item 6: Exhibits

10.1	Form of Restricted Share Award Agreement (Officers and Employees) (Equity Incentive Plan)
31.1	Certification of the President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the President and Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

        “See Exhibit Index following Signature page”.

28

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HEALTHSPRING, INC.
Date: May 2, 2008	By:	/s/ Kevin M. McNamara
		Kevin M. McNamara
		Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)

29

EXHIBIT INDEX

10.1	Form of Restricted Share Award Agreement (Officers and Employees) (Equity Incentive Plan)
31.1	Certification of the President and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of the President and Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

30

EX-10.1

EXHIBIT 10.1

HEALTHSPRING, INC.
RESTRICTED SHARE AWARD AGREEMENT
(Officers and Employees)

     THIS RESTRICTED SHARE AWARD AGREEMENT (this “Agreement”) is made and entered into to be effective as of the ___th day of                     , 2008 (the “Grant Date”), between HealthSpring, Inc., a Delaware corporation (the “Company”), and                                        , (the “Grantee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to such terms in the HealthSpring, Inc. 2006 Equity Incentive Plan (the “Plan”).

     WHEREAS, the Company has adopted the Plan, which permits the issuance of restricted shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”); and

     WHEREAS, pursuant to the Plan, the Committee responsible for administering the Plan has granted an award of restricted shares to the Grantee as provided herein;

     NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

     1. Grant of Restricted Shares.

          (a) The Company hereby grants to the Grantee an award (the “Award”) of                      shares of Common Stock of the Company (the “Shares” or the “Restricted Shares”) on the terms and conditions set forth in this Agreement and as otherwise provided in the Plan.

          (b) The Grantee’s rights with respect to the Award shall remain forfeitable at all times prior to the dates on which the restrictions shall lapse in accordance with Sections 2 and 3 hereof.

     2. Terms and Rights as a Stockholder.

          (a) Except as provided herein and subject to such other exceptions as may be determined by the Committee in its discretion, the “Restricted Period” shall expire                                                                                                                                             .

          (b) The Grantee shall have all rights of a stockholder with respect to the Restricted Shares, including the right to receive dividends and the right to vote such Shares, subject to the following restrictions:

               (i) the Grantee shall not be entitled to delivery of the stock certificate for any Shares until the expiration of the Restricted Period as to such Shares;

               (ii) none of the Restricted Shares may be sold, assigned, transferred, pledged, hypothecated or otherwise encumbered or disposed of during the Restricted Period as to such Shares; and

               (iii) except as otherwise determined by the Committee at or after the grant of the Award hereunder, any Restricted Shares as to which the applicable “Restricted Period” has not expired shall be forfeited, and all rights of the Grantee to such Shares shall terminate, without further obligation on the part of the Company, unless the Grantee remains in the continuous employment of the Company, a Subsidiary or Affiliate for the entire Restricted Period.

          (c) Notwithstanding the foregoing, the Restricted Period shall automatically terminate as to all Restricted Shares awarded hereunder (as to which such Restricted Period has not previously terminated):

               (i) upon the termination of the Grantee’s employment from the Company, a Subsidiary or Affiliate that results from the Grantee’s death or Disability (as determined in the sole discretion of the Committee); or

               (ii) in the event that, within one year following a Change in Control, Grantee’s employment with the Company (or its successor), a Subsidiary or Affiliate is terminated by (I) Grantee for Good Reason (as defined below), or (II) the Company for any reason other than for Cause. For purposes of this Agreement, “Good Reason” means (A) a material reduction in Grantee’s responsibilities, which is not cured within 20 days after written notice thereof to the Company (or its successor); (B) any reduction in Grantee’s annual base salary as in effect immediately prior to a Change in Control; or (C) the relocation by the Company of the office at which the Grantee is to perform the majority of his or her duties following a Change in Control to a location more than 45 miles from the office at which the Grantee worked immediately prior to the Change in Control.

     Any Shares, any other securities of the Company and any other property (except for cash dividends) distributed with respect to the Restricted Shares shall be subject to the same restrictions, terms and conditions as such Restricted Shares.

     3. Termination of Restrictions. Following the termination of the Restricted Period, all restrictions set forth in this Agreement or in the Plan relating to such portion or all, as applicable, of the Restricted Shares shall lapse as to such portion or all, as applicable, of the Restricted Shares, and a stock certificate for the appropriate number of Shares, free of the restrictions and restrictive stock legend, shall, upon request, be delivered to the Grantee or the Grantee’s beneficiary or estate, as the case may be, pursuant to the terms of this Agreement.

     4. Delivery of Shares.

          (a) As of the date hereof, certificates representing the Restricted Shares shall be registered in the name of the Grantee and held by the Company or transferred to a custodian appointed by the Company for the account of the Grantee subject to the terms and conditions of

2

the Plan and shall remain in the custody of the Company or such custodian until their delivery to the Grantee or Grantee’s beneficiary or estate as set forth in Sections 4(b) and (c) hereof or their reversion to the Company as set forth in Section 2(b) hereof.

          (b) Certificates representing Restricted Shares in respect of which the Restricted Period has lapsed pursuant to this Agreement shall be delivered to the Grantee upon request following the date on which the restrictions on such Restricted Shares lapse.

          (c) Certificates representing Restricted Shares in respect of which the Restricted Period lapsed upon the Grantee’s death shall be delivered to the executors or administrators of the Grantee’s estate as soon as practicable following the receipt of proof of the Grantee’s death satisfactory to the Company.

          (d) Each certificate representing Restricted Shares shall bear a legend in substantially the following form or substance:

THE SHARES OF STOCK REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION UNDER THE SECURITES ACT OF 1933 AND UNDER APPLICABLE BLUE SKY LAW OR UNLESS SUCH SALE, TRANSFER, PLEDGE OR OTHER DISPOSITION IS EXEMPT FROM REGISTRATION THEREUNDER.

THIS CERTIFICATE AND THE SHARES OF STOCK REPRESENTED HEREBY ARE SUBJECT TO THE TERMS AND CONDITIONS (INCLUDING FORFEITURE AND RESTRICTIONS AGAINST TRANSFER) CONTAINED IN THE HEALTHSPRING, INC. 2006 EQUITY INCENTIVE PLAN (THE “PLAN”) AND THE RESTRICTED SHARE AWARD AGREEMENT (THE “AGREEMENT”) BETWEEN THE OWNER OF THE RESTRICTED SHARES REPRESENTED HEREBY AND HEALTHSPRING, INC. (THE “COMPANY”). THE RELEASE OF SUCH SHARES FROM SUCH TERMS AND CONDITIONS SHALL BE MADE ONLY IN ACCORDANCE WITH THE PROVISIONS OF THE PLAN AND THE AGREEMENT AND ALL OTHER APPLICABLE POLICIES AND PROCEDURES OF THE COMPANY, COPIES OF WHICH ARE ON FILE AT THE COMPANY.

     5. Effect of Lapse of Restrictions. To the extent that the Restricted Period applicable to any Restricted Shares shall have lapsed, the Grantee may receive, hold, sell or otherwise dispose of such Shares free and clear of the restrictions imposed under the Plan and this Agreement upon compliance with applicable legal requirements.

     6. No Right to Continued Employment. This Agreement shall not be construed as giving Grantee the right to be retained in the employ of the Company or any Subsidiary or Affiliate, and the Company or any Subsidiary or Affiliate may at any time dismiss Grantee from employment, free from any liability or any claim under the Plan.

3

     7. Adjustments. The Committee shall make equitable and proportionate adjustments in the terms and conditions of, and the criteria included in, this Award in recognition of unusual or nonrecurring events (including, without limitation, the events described in Section 4.2 of the Plan) affecting the Company or the financial statements of the Company or of changes in applicable laws, regulations, or accounting principals in accordance with the Plan.

     8. Amendment to Award. Subject to the restrictions contained in the Plan, the Committee may waive any conditions or rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate the Award, prospectively or retroactively; provided that any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would adversely affect the rights of the Grantee or any holder or beneficiary of the Award shall not to that extent be effective without the consent of the Grantee, holder or beneficiary affected.

     9. Withholding of Taxes. If the Grantee makes an election under Section 83(b) of the Code with respect to the Award, the Award made pursuant to this Agreement shall be conditioned upon the prompt payment to the Company of any applicable withholding obligations or withholding taxes by the Grantee (“Withholding Taxes”). Failure by the Grantee to pay such Withholding Taxes will render this Agreement and the Award granted hereunder null and void ab initio and the Restricted Shares granted hereunder will be immediately cancelled. If the Grantee does not make an election under Section 83(b) of the Code with respect to the Award, upon the lapse of the Restricted Period with respect to any portion of Restricted Shares (or property distributed with respect thereto), the Company shall satisfy the required Withholding Taxes as set forth by Internal Revenue Service guidelines for the employer’s minimum statutory withholding with respect to Grantee and issue vested shares to the Grantee without restriction. The Company shall satisfy the required Withholding Taxes by withholding from the Shares included in the Award that number of whole shares necessary to satisfy such taxes as of the date the restrictions lapse with respect to such Shares based on the Fair Market Value of the Shares.

     10. Plan Governs. The Grantee hereby acknowledges receipt of a copy of the Plan and agrees to be bound by all the terms and provisions thereof. The terms of this Agreement are governed by the terms of the Plan, and in the case of any inconsistency between the terms of this Agreement and the terms of the Plan, the terms of the Plan shall govern.

     11. Severability. If any provision of this Agreement is, or becomes, or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Person or the Award, or would disqualify the Plan or Award under any laws deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be stricken as to such jurisdiction, Person or Award, and the remainder of the Plan and Award shall remain in full force and effect.

4

     12. Notices. All notices required to be given under this Grant shall be deemed to be received if delivered or mailed as provided for herein, to the parties at the following addresses, or to such other address as either party may provide in writing from time to time.

To the Company:	HealthSpring, Inc.
	9009 Carothers Parkway
	Suite 501
	Franklin, Tennessee 37067
	Attn: Corporate Secretary
To the Grantee:	The address then maintained with respect to the Grantee in the Company’s records.

     13. Governing Law. The validity, construction and effect of this Agreement shall be determined in accordance with the laws of the State of Delaware without giving effect to conflicts of laws principles.

     14. Successors in Interest. This Agreement shall inure to the benefit of and be binding upon any successor to the Company. This Agreement shall inure to the benefit of the Grantee’s legal representatives. All obligations imposed upon the Grantee and all rights granted to the Company under this Agreement shall be binding upon the Grantee’s heirs, executors, administrators and successors.

     15. Resolution of Disputes. Any dispute or disagreement which may arise under, or as a result of, or in any way related to, the interpretation, construction or application of this Agreement shall be determined by the Committee. Any determination made hereunder shall be final, binding and conclusive on the Grantee and the Company for all purposes.

(remainder of page left blank intentionally)

5

     IN WITNESS WHEREOF, the parties have caused this Restricted Share Award Agreement to be duly executed effective as of the day and year first above written.

HEALTHSPRING, INC.

By:

GRANTEE:

6

EX-31.1

Exhibit 31.1

I, Herbert A. Fritch, President and Chief Executive Officer of HealthSpring, Inc., certify that:

1.	I have reviewed this quarterly report on Form 10-Q of HealthSpring, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2008	/s/ Herbert A. Fritch
	Herbert A. Fritch
	Chairman of the Board of Directors, President, and Chief Executive Officer

31

EX-31.2

Exhibit 31.2

I, Kevin M. McNamara, Chief Financial Officer of HealthSpring, Inc., certify that:

1.	I have reviewed this quarterly report on Form 10-Q of HealthSpring, Inc.;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.
c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 2, 2008	/s/ Kevin M. McNamara
	Kevin M. McNamara
	Executive Vice President and Chief Financial Officer

32

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HealthSpring, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Herbert A. Fritch, Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Herbert A. Fritch Herbert A. Fritch
Chairman of the Board of Directors, President,
and Chief Executive Officer
May 2, 2008

33

EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of HealthSpring, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Kevin M. McNamara, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Kevin M. McNamara Kevin M. McNamara
Executive Vice President and Chief Financial Officer
May 2, 2008

34